The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Tumor Mutation Burden-High Tumors and Pembrolizumab: Biomarker-Guided Immunotherapy

Tissue-agnostic immunotherapy for TMB-high solid tumors with mutation burden as predictive biomarker

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Tumor Mutation Burden-High Tumors and Pembrolizumab: Biomarker-Guided Immunotherapy?

Tumor mutation burden quantifies somatic mutations per coding genome megabase using next-generation sequencing of tumor tissue.

TMB-high definition of at least 10 mutations per megabase derives from KEYNOTE-158 trial supporting pembrolizumab approval.

Pathophysiology involves neoantigen generation from somatic mutations creating tumor-specific peptides for T-cell recognition.

Mutational signatures reflect underlying mutagenic processes including UV exposure, smoking, mismatch repair deficiency and POLE mutations.

Pembrolizumab tissue-agnostic FDA approval represents second biomarker-defined approval following MSI-H/dMMR indication.

Symptoms

Clinical presentation depends on primary tumor type with TMB-high tumors found in melanoma, lung cancer, bladder cancer and others.
Smoking-related cancers including lung and bladder demonstrate higher TMB reflecting tobacco mutagenesis.
UV-related cancers including melanoma and cutaneous squamous cell carcinoma show characteristic mutational signatures with high TMB.
Hypermutator tumors from mismatch repair deficiency or POLE/POLD1 mutations have exceptionally high TMB and excellent immunotherapy responses.
Treatment response patterns and immune-related adverse events parallel those of other anti-PD-1 indications.

Risk Factors

TMB measurement standardization remains challenging with whole-exome sequencing, large gene panels and small panels generating different values.
Cutoff threshold of 10 mutations per megabase varies by platform with commercial assays providing harmonized reporting.
Tumor heterogeneity may produce TMB variability between primary and metastatic samples affecting biomarker assessment.
Co-mutations including STK11/KEAP1 in lung cancer may attenuate immunotherapy benefit even in TMB-high disease.
Tissue requirements for adequate mutation calling require sufficient tumor cellularity and DNA quality for reliable assessment.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Treatment-resistant solid tumors after standard therapy may benefit from comprehensive genomic profiling including TMB assessment.
  • Tumors traditionally responsive to immunotherapy including melanoma, lung cancer and bladder cancer warrant TMB consideration in treatment planning.
  • Rare tumors without standard immunotherapy approval may have TMB-high status enabling pembrolizumab access through tissue-agnostic indication.
  • Comprehensive genomic profiling at tertiary cancer centers provides standardized TMB reporting alongside other actionable biomarkers.
  • Immune-related adverse events during pembrolizumab require recognition and management with most successfully addressed with treatment modification.

Treatment Methods

01
Pembrolizumab 200 mg IV every 3 weeks or 400 mg every 6 weeks demonstrates activity in TMB-high tumors with durable responses.
02
Treatment duration up to 2 years with response continuation in some patients beyond progression by some criteria.
03
Immune-related adverse event monitoring including endocrine, hepatic, pulmonary, gastrointestinal and dermatologic assessment supports safety.
04
Combination strategies with chemotherapy, radiotherapy or other immunotherapy agents under investigation for improved outcomes.
05
Multidisciplinary care including medical oncology, molecular pathology, palliative care and comprehensive genomic profiling supports personalized therapy decisions integrating biomarkers with clinical factors for evidence-based treatment selection.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.